A while back now the research group at M. D. Anderson Cancer Center initiated a Phase II clinical trial of a drug called tandutinib in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) who had already had taxane-based chemotherapy. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer | Tagged: castration-resistant, mCRPC, PDGF, PDGFR, platelet-derived growth factor, receptor, tandutinib | Leave a comment »
